TITLE

COMMENTARY: Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients

AUTHOR(S)
Massie, Barry M.
PUB. DATE
March 2005
SOURCE
ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p37
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients. isosorbide dinitratc plus hydralazine (ID + H) should become standard care in black patients with systolic heart failure (HF) who fulfill the African-American Heart Failure Trial (A-HeFT) entry criteria and arguably in patients with milder symptoms. For whites, ID + H might be used empirically, but primarily only in patients who continue to have evidence of progression despite regimens that include β-blockers, angiotensin-converting enzyme inhibitors and aldosterone blockers.
ACCESSION #
16486576

 

Related Articles

  • Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients.  // ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p37 

    The article cites a study, which discusses the effectiveness of a fixed dose of isosorbide dinitratc plus hydralazine (ID + H) to that of placebo in black patients with New York Heart Association (NYHA) class III or IV heart failure (HF) with dilated ventricles. 1050 patients were included for...

  • Tratamentul farmacologic al insuficienÅ£ei cardiace sistolice. DIACONU, CAMELIA; BĂLĂCEANU, ALICE // Romanian Journal of Medical Practice;2010, Vol. 5 Issue 1, p9 

    Heart failure is a disease with considerable socio-economic impact. Systolic dysfunction is most often defined as an ejection fraction below 35-40%. Two classes of agents have become the cornerstone of therapy to dealy or halt progression of cardiac dysfunction and improve mortality:...

  • VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Velazquez, Eric J.; Pfeffer, Marc A.; McMurray, John V.; Maggioni, Aldo P.; Rouleau, Jean-Lucien; Van de Werf, Frans; Kober, Lars; White, Harvey D.; Swedberg, Karl; Leimberger, Jeffrey D.; Gallo, Paul; Sellers, Mary Ann; Edwards, Susan; Henis, Marc; Califf, Robert M.; VALIANT Investigators, for the // European Journal of Heart Failure;Aug2003, Vol. 5 Issue 4, p537 

    Background: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial compared outcomes with: (1) angiotensin-converting enzyme inhibition (ACEI) with the reference agent captopril; (2) angiotensin-receptor blockade (ARB) with valsartan; or (3) both in patients with heart failure (HF) and/or...

  • Results From EMPHASIS-HF.  // MD Conference Express;Jan2011, p17 

    The article examines the effect of eplerenone, a selective aldosterone antagonist, on patients with NYHA Class II heart failure. It was found that the addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients. The primary outcome of cardiovascular (CV)...

  • Isosorbide Dinitrate Plus Hydralazine in Black Patients. Ebell, Mark // American Family Physician;3/1/2005, Vol. 71 Issue 5, p972 

    Discusses research being done on the effectiveness of combined hydralazine and isosorbide dinitrate in improving outcomes in Black patients with systolic heart failure. Reference to a study by A. L. Taylor et al, published in the November 11, 2004 issue of the "New England Journal of Medicine";...

  • Angiotensin receptor blockers not equivalent to ACE inhibitors for heart failure. Slawson, James G.; Meurer, Linda N. // Journal of Family Practice;Jun2002, Vol. 51 Issue 6, p508 

    The article examines the effectiveness of angiotensin receptor blockers (ARB) in the treatment of heart failure. Various studies have been identified comparing ARB with placebo or angiotensin-converting enzyme (ACE) inhibitors published before May 2001 through a search of relevant databases....

  • Nitric oxide enhancement improves survival in African Americans with heart failure.  // Geriatrics;Feb2005, Vol. 60 Issue 2, p14 

    Explains that a fixed-dose combination of isosorbide dinitrate/hydralazine added to standard background therapy improves survival in African Americans with advanced heart failure. Nitric-oxide-enhancing medication; Randomized clinical trial; Reduction in the rate of first hospitalization for...

  • Effects of ACE Inhibitors or β-Blockers in Patients Treated with the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial. Ghali, Jalal K.; Tam, S William; Ferdinand, Keith C.; Lindenfeld, JoAnn; Sabolinski, Michael L.; Taylor, Anne L.; Worcel, Manuel; Curry, Charles L.; Cohn, Jay N. // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 4, p373 

    BACKGROUND: In the A-HeFT (African-American Heart Failure Trial), treatment of African-American patients with New York Heart Association (NYHA) class III/IV heart failure (HF) with fixed-dose combination (FDC) of isosorbide dinitrate/hydralazine (I/H) reduced mortality and morbidity and improved...

  • Role of aldosterone blockade in managing heart failure: New and emerging treatment options.  // American Journal of Health-System Pharmacy;5/1/2004 Supplement 2, Vol. 61, p23 

    Focuses on the role of aldosterone blockade in managing heart failure. Social and economic impact of heart failure in the U.S.; Role of neurohormonal mediators in renin-angiotensin-aldosterone and sympathetic nervous system in heart failure.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics